Selinexor for reducing blood cell counts in myeloproliferative neoplasms
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests the drug selinexor as a single treatment to lower very high blood cell counts or shrink an enlarged spleen in patients with certain chronic blood cancers (polycythemia vera, essential thrombocythemia, or primary myelofibrosis). It may be an option if standard treatments are not working or cause side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a diagnosis of polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
- You must need treatment to reduce blood counts or symptoms, such as very high platelet count, high white blood cell count, an enlarged spleen, or weight loss.
- You must be willing to stop other treatments or have not been able to tolerate standard therapies like hydroxyurea or interferon.
- You must be generally healthy enough to carry out daily activities (performance status 0-2) and have adequate organ function.
- You must agree to use contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This trial tests whether giving two medicines, called selinexor and melphalan, twice a week after a stem cell transplant can help prevent acute myeloid leukemia from coming back. It's for people with high-risk AML who are 55 or older and whose cancer is in remission before the transplant.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This trial studies selinexor, a medicine taken by mouth, to slow or treat intermediate- or high-risk smoldering multiple myeloma before it becomes symptomatic. It may help some people reduce disease progression, based on how well the treatment controls the abnormal plasma cells.
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Hear when a new Myeloproliferative Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.